Insmed Incorporated (INSM) financial statements and ratios from SEC XBRL: revenue $1.1B (TTM), net margin -210.5%, revenue growth 296.1% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $606.42M |
| Revenue (TTM) | $1.1B |
| Net Margin | -210.5% |
| Operating Margin (TTM) | -73.9% |
| Net Debt / EBITDA | 0.0 |
| Revenue Growth (YoY) | 296.1% |
| EPS Growth (YoY) | -96.5% |
| FCF Growth (YoY) | -54.5% |
| Price / Book | 36.27 |
| Price / Sales | 24.15 |
| FCF Yield | -2.9% |
| Altman Z-Score | 6.33 (safe) |
| Piotroski F-Score | 4/9 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
INSM overview · INSM earnings · INSM KPIs · INSM documents · INSM ownership · INSM peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.